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receptors in the tonic and reflex control of
cardiac vagal outflow in the rat
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Abstract
Background: Cardiac vagal preganglionic neurons (CVPN) are responsible for the tonic, reflex and respiratory
modulation of heart rate (HR). Although CVPN receive GABAergic and glutamatergic inputs, likely involved in
respiratory and reflex modulation of HR respectively, little else is known regarding the functions controlled by
ionotropic inputs. Activation of g-protein coupled receptors (GPCR) alters these inputs, but the functional
consequence is largely unknown. The present study aimed to delineate how ionotropic GABAergic, glycinergic and
glutamatergic inputs contribute to the tonic and reflex control of HR and in particular determine which receptor
subtypes were involved. Furthermore, we wished to establish how activation of the 5-HT1A GPCR affects tonic and
reflex control of HR and what ionotropic interactions this might involve.
Results: Microinjection of the GABAA antagonist picrotoxin into CVPN decreased HR but did not affect baroreflex
bradycardia. The glycine antagonist strychnine did not alter HR or baroreflex bradycardia. Combined microinjection
of the NMDA antagonist, MK801, and AMPA antagonist, CNQX, into CVPN evoked a small bradycardia and
abolished baroreflex bradycardia. MK801 attenuated whereas CNQX abolished baroreceptor bradycardia. Control
intravenous injections of the 5-HT1A agonist 8-OH-DPAT evoked a small bradycardia and potentiated baroreflex
bradycardia. These effects were still observed following microinjection of picrotoxin but not strychnine into CVPN.
Conclusions: We conclude that activation of GABAA receptors set the level of HR whereas AMPA to a greater
extent than NMDA receptors elicit baroreflex changes in HR. Furthermore, activation of 5-HT1A receptors evokes
bradycardia and enhances baroreflex changes in HR due to interactions with glycinergic neurons involving
strychnine receptors. This study provides reference for future studies investigating how diseases alter
neurochemical inputs to CVPN.
Background
Cardiac vagal preganglionic neurons (CVPN) are found
predominantly in the nucleus ambiguus (NA) as well as
dorsal motor nucleus of the vagus (DMNV) and in the
intermediate zone (IZ) between these two nuclei [1-3].
Activation of CVPN has negative chronotropic, dromo-
tropic and ionotropic effects on the heart [4-6] and the
activity of these neurons is increased in response to bar-
oreceptor stimulation [7-9] and inhibited during inspira-
tion [10,11].
Surprisingly little is known about the functional signif-
icance of inputs to CVPN mediated by either ionotropic
or g-protein coupled receptors (GPCR). CVPN receive
substantial inputs from ionotropic receptors. Microinjec-
tion of the GABAA receptor antagonist bicuculline into
the NA evokes a profound decrease in HR [12] demon-
strating that there is a large GABAergic input to CVPN
that plays a role in setting the tonic level of heart rate
(HR). GABAergic inputs also appear to mediate the
inspiratory related inhibition of CVPN and may play a
role in generating respiratory sinus arrhythmia (RSA)
[13]. Although glycine evokes tachycardia when injected
unilaterally into the NA [14], the role of glycinergic
inputs in both the tonic and reflex control of cardiac
vagal outflow have not been systematically explored.
Glutamatergic inputs, conversely, mediate baroreceptor
dependent excitation of CVPN [7,15-17], however the
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determined.
The influence some GPCR have in regulating CVPN
has been determined. For example, activation of seroto-
nin-1a/7, dopamine, μ-opioid or neurokinin-1 receptors
within the NA decreases HR whereas activation of
opioid-receptor like receptor-1 increases HR, demon-
strating that activation of some GPCR can differentially
alter the tonic level of HR [18-21]. The role of these
GPCR, or for that matter others, however, in the reflex
modulation of HR is not well understood. Systemic acti-
vation of serotonin-1A (5-HT1A) receptors potentiates
baroreflex mediated bradycardia [22,23]. Central admin-
istration of the selective 5-HT1A antagonist, WAY-
100635, attenuates baroreflex sensitivity suggesting a
pivotal role for 5-HT1A receptors in the maintenance of
reflex cardiac vagal outflow [24]. Furthermore, 5-HT1A
receptor modulation of reflex cardiac vagal outflow is
absent in the flinders sensitive line rat, an animal model
of depression, which exhibits reduced BRS [23], thus
highlighting the clinical importance of functional 5-
HT1A receptor control of cardiac vagal outflow.
How activation of 5-HT1A receptors produces brady-
cardia and enhances baroreflex bradycardia is unknown.
Speculation suggests that as the 5-HT1A receptor is an
inhibitory GPCR, the mechanism must involve an inter-
action with inhibitory ionotropic inputs to CVPN [25].
In keeping with this hypothesis, application of 8-OH-
DPAT in vitro attenuates presynaptic GABAergic and
glycinergic inputs to CVPN [26,27]; however the func-
tional significance of these inputs is unknown. Whether
or not the effects of 5-HT1A activation on HR or BRS
are mediated by GABAergic and/or glycinergic inhibi-
tion of CVPN in the ventrolateral medulla has not been
investigated in vivo.
The initial aim of this study was to assess comprehen-
sively, in the rat, the roles of GABAA, strychnine-sensi-
tive glycine and NMDA and AMPA receptors within
regions of the medulla containing CVPN in the tonic
and reflex control of HR. Secondly, we investigated if
activation of the 5-HT1A receptor evoked bradycardia
and potentiation of baroreflex bradycardia was depen-
dent upon GABAergic or glycinergic neurotransmission
to CVPN.
Methods
All experiments were approved by Macquarie University
animal ethics committee and conducted in accordance
w i t ht h eA u s t r a l i a nC o d eo fP r a c t i c ef o rt h eC a r ea n d
Use of Animals for Scientific Purposes. Animals were
housed on a 12 h light dark cycle (lights on at 6 am)
with food and water available ad libitum.
Adult male Sprague Dawley (n = 34, 300-600 g) rats
were anaesthetised with ethyl carbamate (urethane 1.3
g/kg ip; Sigma Aldrich Ltd.). Depth of anaesthesia was
assessed regularly using reflex responses to tactile (cor-
neal stroking) stimuli. Additional doses of urethane
(0.13 g/kg IV) were administered as required. The right
femoral artery and vein were cannulated to enable
recording of arterial pressure (AP) and to administer
drugs, respectively. A tracheotomy was performed. Rec-
tal temperature was monitored and maintained at 37°C,
using a thermostatically controlled electric blanket (Har-
vard Apparatus, USA) and an infrared-heating source.
Animals were then placed in a stereotaxic frame and
artificially ventilated with oxygen enriched room air.
Peak expired CO2 was continuously monitored and
maintained between 3.5-4.5%. A laminectomy was per-
formed at C8, the spinal cord transected, and an occipi-
tal craniotomy was performed to expose the dorsal
surface of the medulla.
Experimental Protocol
Location of CVPN
In all animals, sites were located within the ventrolateral
medulla from which vagally mediated bradycardia was
evoked by 50 nl microinjections of L-glutamate (100
mM; Sigma Aldrich Ltd.). Microinjections of L-gluta-
mate were made in a region encompassing 1.4-2.0 mm
lateral to the midline, 0-1.2 mm rostral to the calamus
scriptorius and between 1.5-3.5 mm ventral to the dor-
sal surface of the medulla. Tracks were separated by at
least 0.3 mm and sites within a track by 0.5 mm or
more. At each injection site the change in HR and/or
presence of atrioventricular (AV) block, determined by
the absence of QRS complex on the ECG waveform,
were determined. The location of CVPN was identified
as a site where a bradycardia > 50 bpm or AV block
was evoked by microinjection of L-glutamate. In each
experiment, 4 sites (2 per side) where the largest brady-
cardia or AV block concurrent with bradycardia were
evoked, were targeted in order to cover the entire ros-
tro-caudal extent of CVPN. At the end of each experi-
ment these sites were marked with pontamine sky blue
and the rat euthanased with potassium chloride (3 M).
The medulla was removed and placed in 4% formalde-
hyde in phosphate buffer (0.1 M). Coronal sections (100
μm) were cut with a vibrating microtome and stained
with cresyl violet for histological analysis.
Effect of spinal cord transection on basal cardiovascular
parameters
In 7 animals the effect of spinal cord transection on HR,
mean AP (MAP) and BRS was examined. MAP and HR
were calculated over an 80 sec period immediately prior
to spinal cord transection and after the peak fall in AP
was reached and maintained at a steady level (roughly
30-45 mins post transection). Baroreceptor function
curves were generated using bolus injections of
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spinal cord transection and after the peak fall in AP,
and BRS was then calculated.
Drug microinjections
Twenty-five animals received drug microinjections into
cardioinhibitory sites of the medulla. Once the two most
cardiac responsive sites per side (i.e. four sites in total)
were located, the drug to be tested (as indicated below)
was microinjected into each of the sites (100 nl per
injection, 2 injections per side) identified. The criteria
for a cardiac responsive site were bradycardia exceeding
5 0b p mo rA Vb l o c ka n dt h a tt h e4s i t e sc o v e r e dt h e
rostro-caudal extent of CVPN and were ~600 μm apart.
Animals either received two 100 nl bilateral microin-
jections of muscimol (GABAA agonist, 100 mM n = 4;
Sigma-Aldrich Inc.), picrotoxin (GABAA receptor
antagonist, 2 mM n = 6 [28]), bicuculline methiodide
(GABAA a n t a g o n i s t ,0 . 4m Mn=4[ 2 9 ] ;S i g m a - A l d r i c h
Inc.), strychnine hydrochloride (strychnine sensitive gly-
cine receptor antagonist, 3 mM n = 4 [30]; Sigma-
Aldrich Inc.), MK801 (NMDA receptor antagonist, 5
mM n = 4 [31]; Sigma-Aldrich Inc.) or CNQX (AMPA
receptor antagonist, 2 mM n = 3 [32]; Research Biome-
dical International). Prior to drug microinjection and
again at nadir cardiac response, baroreceptor function
was assessed using changes in AP in response to bolus
injections of phenylephrine (10 μg/kg in 0.1 ml IV). HR
was calculated over three 80 second segments prior to
drug microinjection and at the peak HR response. In
rats receiving MK801 (n = 4), CNQX (2 mM) was then
microinjected into the vicinity of CVPN following exam-
ination of baroreceptor function in order to examine
effects of combined NMDA and AMPA receptor block-
ade on cardiac vagal function. In rats receiving microin-
jection of picrotoxin or strychnine, 8-OH-DPAT (0.1
mg/kg IV) was administered and baroreceptor curves
generated again. In a separate cohort of rats, 8-OH-
DPAT (0.1 mg/kg IV, n = 9) was administered and bar-
oreceptor function curves generated at the peak cardio-
vascular response.
Data Analysis
Data was acquired using CED1401 analogue-digital con-
verter hardware and analysed off-line using Spike 2 soft-
ware v. 6.2 (both from CED, Cambridge, UK).
BRS
The index method was used to calculate BRS. The index
method calculates BRS as the ratio between the decrease
in HR and increase in MAP (ΔHR/ΔMAP) induced by
phenylephrine. BRS estimated using this method does
not differ from BRS estimated using linear regression
analysis [33]. BRS calculated from each replicate curve
generated was averaged to give one final BRS estimate.
Statistical Analysis
All data are presented as mean ± SEM. Paired or ratio t-
tests were used to determine if each treatment affected
HR or BRS. One-way ANOVA was used to compare
effect of 8-OH-DPAT on HR under control conditions
versus following picrotoxin or strychnine. P <0 . 0 5w a s
considered significant (GraphPad Prism v5).
Results
Effect of lower cervical spinal cord transection on basal
cardiovascular variables
In 7 animals, the effect of transection of the spinal cord
at the 8th cervical segment on MAP, HR and baroreflex
function was determined. Spinal cord transection evoked
a profound fall in MAP (98.2 ± 4.2 v 60.2 ± 4.6 mmHg
P < 0.001) and reduced resting HR (344 ± 15 v 302 ±
10 bpm P < 0.05). This hypotensive condition caused by
reduced sympathetic activity also ensures that the baror-
eceptors are fully unloaded. Baroreflex mediated changes
in HR, in response to induced increases in AP with phe-
nylephrine, were unaffected by spinal cord transection
and both the gain (0.76 ± 0.18 v 0.43 ± 0.10 bpm/
mmHg P = 0.0955) and range (45 ± 10 v 37 ± 9 bpm P
= 0.4637) of the baroreflex was not altered.
Location and verification of CVPN sites in the medulla
The medulla was mapped by glutamate microinjection
to determine the sites from which a vagally mediated
bradycardia could be evoked. Vehicle injection into
these regions did not affect resting HR (340 ± 5 vs. 337
± 10 bpm before vs. after vehicle injection, P = 0.6595 n
= 3 and as previously described [19,20,34]). To verify
that the sites targeted contained CVPN and that the
entire rostro-caudal distribution of CVPN in the
medulla could be targeted with two bilateral microinjec-
tions, bilateral microinjections of the GABAA agonist
muscimol were made in 4 animals. The effects of musci-
mol on HR and baroreflex function are shown in Figure
1A. HR rose to 356 ± 15 bpm from 282 ± 3 bpm (P <
0.05, Figure 1B) and this was associated with a reduction
in BRS (0.66 ± 0.21 bpm/mmHg v 0.10 ± 0.02 bpm/
mmHg, P < 0.05, Figure 1C), effectively abolishing bar-
oreflex control of HR. A similar effect on the baroreflex
has been described previously [35]. This confirms that
the sites identified here are the source of cardiac vagal
outflow and that the majority of CVPN could be tar-
geted with two bilateral microinjections.
Role of ionotropic GABAA and strychnine sensitive glycine
receptors in areas of the medulla containing CVPN in the
tonic and baroreflex control of HR
The effects of bilateral microinjections of the GABAA
antagonist picrotoxin on HR and baroreflex function are
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found reduction in HR (from 300 ± 4 bpm to 176 ± 13
bpm, P < 0.01, Figure 2D); however, in contrast to acti-
vation of GABAA receptors (Figure 1D), blockade of
GABAA receptors did not alter BRS (Figure 2E). Bilat-
eral microinjection of bicuculline, another GABAA
antagonist, as illustrated in Figure 2B, also evoked a pro-
found decrease in HR (335 ± 11 v 185 ± 30 bpm, con-
trol v bicuculline P < 0.01 n = 4) decreasing HR to a
level similar to that seen following picrotoxin (P = 0.76).
However bicuculline consistently evoked arrhythmias
possibly resulting from the blockade of after-hyperpolar-
isation potentials (IAHP) arising due to the blockade of
SK channels [36]. As a result BRS could not be analysed.
The effect of bilateral microinjection of strychnine on
HR and baroreflex function is shown in Figure 2C. Inhi-
bition of strychnine-sensitive glycine receptors had no
effect on resting HR (296 ± 27 bpm v 272 ± 13 bpm P
= 0.2051 Figure 2D) or BRS (0.44 ± 0.17 bpm/mmHg v
0.49 ± 0.13 bpm/mmHg, P = 0.60 Figure 2E).
Role of ionotropic glutamate receptors in areas of the
medulla containing CVPN in the tonic and baroreflex
control of HR
The effects of bilateral inhibition of NMDA or AMPA
receptors in medullary regions containing CVPN on HR
and baroreflex function are shown in Figure 3A and 3B
respectively. Blockade of NMDA receptors with MK801
or AMPA receptors with CNQX did not change resting
HR (Figure 3D). BRS, however, was reduced by approxi-
mately 40% in response to blockade of NMDA receptors
(0.49 ± 0.06 v 0.29 ± 0.06 bpm/mmHg, P <0 . 0 5F i g u r e
3E) and 83% in response to blockade of AMPA recep-
tors (0.40 ± 0.11 v 0.07 ± 0.01 bpm/mmHg, P <0 . 0 5
Figure 3E).
The effects of combined AMPA/NMDA receptor
blockade in the region containing CVPN on HR and
baroreflex function are shown in Figure 3C. A small
reduction in resting HR (306 ± 16 bpm v 284 ± 17 bpm
P < 0.05, Figure 3D) was observed and BRS was reduced
by approximately 85% (0.40 ± 0.11 v 0.06 ± 0.01 bpm/
mmHg, P < 0.05 Figure 3E). BRS following combined
AMPA/NMDA receptor blockade was similar to that
following AMPA receptor blockade alone (P = 0.33).
Role of GABAergic and glycinergic neurotransmission in
regions of the medulla containing CVPN in cardio-vagal
responses to 5-HT1A receptor activation
The effect of intravenous administration of 8-OH-DPAT
(0.1 mg/kg) on HR and baroreflex function is illustrated
in Figure 4A. Activation of 5-HT1A receptors with 8-
OH-DPAT evoked a small but significant decrease in
resting HR (from 310 ± 17 bpm control to 296 ± 15
bpm, P < 0.05 Figure 4D) and a 40% increase in BRS
(from 0.49 ± 0.07 bpm/mmHg to 0.73 ± 0.14 bpm/
mmHg, P < 0.05 Figure 4E) as previously described [23].
The effect of intravenous 8-OH-DPAT on HR and
baroreflex function following microinjection of picro-
t o x i no rs t r y c h n i n ei ss h o w ni nF i g u r e4 Ba n d4 C
respectively. Following microinjection of picrotoxin,
Figure 1 Verification that dual bilateral microinjections in the
ventral medulla inhibits cardiac vagal outflow. A representative
trace is provided in panel A showing that microinjection of
muscimol (100 mM, 100 nl) into four regions of the medulla where
bradycardia greater than 50 bpm was evoked by prior
microinjection of L-glutamate (100 mM, 50 nl) increases resting
heart rate (HR) and prevents baroreflex mediated bradycardia.
Grouped data (n = 4) shows that microinjection of muscimol into
these four sites evokes a large increase in HR (panel B) and
dramatically reduces baroreflex sensitivity (BRS, panel C). * P < 0.05.
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Page 4 of 11Figure 2 Role of ionotropic GABAA and strychnine sensitive glycine receptors in areas of the medulla containing cardiac vagal
preganglionic neurons in the tonic and baroreflex control of HR. Panel A and B show the effects of bilateral microinjection of the GABAA
antagonists bicuculline (0.4 mM, n = 4) and picrotoxin (2 mM, n = 6) respectively on resting heart rate (HR) and baroreflex evoked bradycardia
induced using phenylephrine (PE). Both bicuculline and picrotoxin evoked large and similar decreases in resting HR. Bicuculline, however, evoked
arrhythmia and the effects on baroreflex bradycardia could not be quantified. Panel C shows the effects of bilateral microinjection of strychnine
(3 mM, n = 4) on resting HR and baroreflex bradycardia. Group data (panels D and E) shows that picrotoxin evoked a large decrease in resting
HR whereas strychnine had no effect (panel D). Neither picrotoxin nor strychnine affected baroreflex bradycardia or baroreflex sensitivity (BRS,
panel E). *** P < 0.001.
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decreased resting HR (from 205 ± 13 bpm to 181 ± 14
bpm, P < 0.01 Figure 4D) and increased BRS (from 0.45
± 0.08 bpm/mmHg to 0.59 ± 0.09 bpm/mmHg, P < 0.05
Figure 4E). Following microinjection of strychnine,
intravenous administration of 8-OH-DPAT (0.1 mg/kg)
no longer evoked a decrease in HR (283 ± 15 bpm v
285 ± 13 bpm P = 0.75 Figure 4D) or an increase in
BRS (0.49 ± 0.13 bpm/mmHg v 0.41 ± 0.10 bpm/
mmHg, P = 0.29 Figure 4E). The inhibitory actions of 8-
OH-DPAT on HR were unaffected by prior microinjec-
tion of picrotoxin but abolished through prior microin-
jection of strychnine (-13 ± 5 bpm vs. -23 ± 6 bpm vs. 2
± 5 bpm control vs. picrotoxin vs. strychnine P < 0.05).
Discussion
The major findings of the present study are that in
regions of the brain containing CVPN: 1. Activation of
GABAA receptors is required to set the resting level of
HR; 2. Baroreflex mediated bradycardia is dependent
upon activation of AMPA receptors to a greater extent
than NMDA receptors 3. Strychnine sensitive glycine
receptors are not involved in the tonic or reflex control
of HR but their activation is required to enable the bra-
dycardiac and baroreflex facilitating effects of 5-HT1A
receptor activation.
Role of ionotropic GABA and glycine receptors in regions
of the medulla containing CVPN in the tonic and reflex
control of HR
We have shown that GABAA receptors, but not strych-
nine sensitive glycine receptors, are required for setting
the level of HR. That GABAA receptors are vital for set-
ting the tonic level of vagal outflow to the heart is well
established and our findings support the notion that
CVPN receive a substantial GABAergic input [12,35].
The bradycardia evoked following bilateral microinjec-
tion of either picrotoxin or bicuculline is likely due to
blockade of postsynaptic GABAA receptors on CVPN as
focal application of picrotoxin blocks inhibitory
Figure 3 Role of ionotropic glutamate receptors in areas of the medulla containing CVPN in the tonic and baroreflex control of HR.
Panel A illustrates the effects of bilateral microinjection of the NMDA antagonist MK801 (5 mM, n = 4), panel B illustrates the effects of bilateral
microinjection of the AMPA antagonist CNQX (2 mM, n = 3) and panel C illustrates the effects of bilateral microinjection of CNQX following
MK801 (n = 4) on resting heart rate (HR) and baroreflex bradycardia. Panel D illustrates the effects of these antagonists on resting HR. Neither
MK801 nor CNQX alone altered resting HR; however, combined microinjection of these antagonists evoked a small but significant decrease in
resting HR. In panel E the effect of these antagonists on baroreflex function are shown. Microinjection of MK801 evoked a modest decrease in
baroreflex sensitivity (BRS) whereas microinjection of CNQX dramatically reduced BRS and abolished all baroreflex function. Combined
microinjection of MK801 and CNQX reduced BRS to levels similar to that observed following microinjection of CNQX alone. * P < 0.05, ** P <
0.01.
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neurons in cardio-vagal responses to 5-HT1A receptor activation. Panel A illustrates the effects of intravenous injection of the 5-HT1A
agonist 8-OH-DPAT (0.1 mg/kg, n = 9) on heart rate (HR) and baroreflex bradycardia. Panels B and C shows the intravenous injection of 8-OH-
DPAT on HR and baroreflex bradycardia following prior microinjection of the GABAA antagonist picrotoxin (2 mM, n = 6) and glycine antagonist
strychnine (3 mM, n = 4) into regions of the medulla containing cardiac vagal preganglionic neurons respectively. Panel D shows that an
injection of 8-OH-DPAT alone evokes a small bradycardia which is not altered by prior microinjection of picrotoxin. Prior microinjection of
strychnine prevents this bradycardia. Panel E shows that injections of 8-OH-DPAT alone increase baroreflex sensitivity (BRS). This increase in BRS is
still seen following prior microinjection of picrotoxin but not strychnine. * P < 0.05, ** P < 0.01.
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bilateral microinjection of strychnine does not alter rest-
ing HR is in contrast with previous reports where uni-
lateral microinjection of strychnine into the NA
decreased resting HR suggesting a role for strychnine
sensitive glycine receptorsi nt h ec o n t r o lo fH Ra tl e a s t
in cats [12]. Nevertheless, in rats, microinjection of
strychnine does not affect the tachycardic response to
microinjection of glycine in cardioinhibitory sites of the
medulla [14]. Together with our results this suggests
that strychnine-sensitive glycine receptors are not
involved in the tonic control of cardiac vagal outflow in
the rat.
While the role of GABAA and strychnine sensitive gly-
cine receptors in the tonic control of HR has been
investigated previously, how these receptors are involved
in evoking reflex changes in HR has not. It has been
hypothesised that disinhibiting CVPN through inhibition
of GABAergic or glycinergic inputs to CVPN can
improve BRS through the facilitation of excitatory inputs
to CVPN [23,38,39]. We tested this and showed that
bilateral microinjection of picrotoxin or strychnine did
not alter BRS. This demonstrates for the first time that
neither GABAA nor strychnine sensitive glycine recep-
tors are required for the baroreflex activation of cardiac
vagal outflow, at least in regions of the medulla contain-
ing CVPN.
Role of ionotropic glutamate receptors in regions of the
medulla containing CVPN in the tonic and reflex control
of HR
Activation of ionotropic glutamate receptors, which are
found on the soma and dendrites of CVPN [40], with L-
glutamate produces a decrease in HR (as seen here to
identify CVPN and previously [18,20,34]). However,
combined blockade of NMDA and AMPA receptors did
not evoke an expected increase in HR, but paradoxically
a bradycardia. This confirms the study of Guyenet et al
[15] who observed bradycardia following microinjection
of kynurenic acid into the region of the NA. We
extended these findings by showing that blockade of
either NMDA or AMPA receptors alone did not evoke
any change in HR suggesting that there is not a substan-
tial tonic ionotropic glutamatergic input to CVPN. In
light of the small bradycardia evoked by combined
receptor blockade, it is possible that there is some tonic
glutamatergic control of inhibitory inputs to CVPN.
Glutamatergic modulation, involving both NMDA and
AMPA receptors, of GABAergic inputs to CVPN in the
DMNV but not NA has been described previously [41].
It remains possible that glutamatergic regulation of gly-
cinergic inputs may exist in the NA.
Baroreflex mediated changes in parasympathetic out-
flow to the heart occur via glutamatergic inputs from
the nucleus tractus solitarius (NTS) to cardiac vagal
preganglionic neurons (CVPN) located principally in the
nucleus ambiguus (NA). Several lines of evidence sup-
port this: Stimulation of the baroreflex in vivo evokes a
reflex increase in CVPN activity which correlates with
the reflex bradycardia evoked [7]; Microinjection
kynurenic acid, a non-specific glutamate antagonist, into
the region of the NA prevents vagally mediated barore-
flex bradycardia [15]; Electrical stimulation of depressor
sites within the NTS increases CVPN unit activity in
vivo [17]; Stimulation of the NTS in vitro evokes excita-
tory postsynaptic currents in CVPN which are inhibited
by combined blockade of NMDA and AMPA receptors
[16].
While there is substantial evidence to indicate that
glutamatergic inputs to CVPN are necessary for the gen-
eration of baroreflex bradycardia, the receptor subtype(s)
responsible for eliciting these reflex changes is
unknown. Both NMDA and AMPA receptors are
located on the soma and dendrites of CVPN [40]. In the
present study, inhibition of NMDA receptors modestly
attenuated BRS whereas blockade of AMPA receptors
completely abolished baroreflex control of HR. The
reduction in BRS evoked by CNQX alone was similar to
that following combined NMDA/AMPA receptor block-
ade. Thus, the integrity of AMPA receptors within
CVPN alone is critical to the baroreflex activation of
cardiac vagal outflow whereas NMDA receptors play a
more minor role. This contrasts with the responses
obtained in other vagal motoneurons in the NA, where
NMDA receptors mediate the effects evoked by stimula-
tion of the NTS [42].
Our findings also contrast with those some of those
described within other medullary regions of the barore-
flex arc. In the NTS some report that baroreflex neuro-
transmission is dependent upon NMDA receptor
activation [43] and others, non-NMDA receptor activa-
tion [44]. Nevertheless, the majority report that both
receptor subtypes are required for full expression of the
baroreceptor reflex [45-49]. The caudal ventrolateral
medulla, which also receives baroreceptor input from
the NTS, is excited by activation of both AMPA and
NMDA receptors [50]. A greater dependence on AMPA
over NMDA receptors for the full expression of barore-
ceptor mediated bradycardia therefore appears to be
unique to the vagal outflow of the baroreflex.
Role of ionotropic GABAergic and glycinergic
neurotransmission within regions of the medulla
containing CVPN in the cardio-vagal responses to 5-HT1A
receptor activation
W eh a v ec o n f i r m e dp r e v i o u sf i n d i n g sw h i c hd e m o n -
strate that systemic administration of 8-OH-DPAT
results in a vagally mediated bradycardia and
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We have then extended these findings to determine the
central mechanisms responsible for this 8-OH-DPAT
evoked potentiation in reflex bradycardia.
8-OH-DPAT is an agonist at both 5-HT1A and 5-HT7
receptors [51], although the actions at the 5-HT1A
receptor are presumed responsible for the potentiation
in reflex vagal outflow. Kellett and others [24] demon-
strated that intracisternal administration of WAY-
100635, the 5-HT1A selective antagonist, attenuates bar-
oreflex mediated bradycardia indicating that 5-HT1A
receptors in the medulla are responsible for the facilita-
tion of baroreflex bradycardia evoked by 8-OH-DPAT.
Wang and Ramage [25] further showed that iontophor-
esis of WAY-100635 onto CVPN attenuates the increase
in activity of these neurons in response to stimulation of
pulmonary C fibres.
The most logical explanation for the 8-OH-DPAT
mediated facilitation of baroreflex bradycardia is through
inhibition of GABAergic or glycinergic inputs to CVPN.
In support of this hypothesis, in slice preparation, appli-
cation of 8-OH-DPAT inhibits both GABAergic and gly-
cinergic inputs to CVPN [26,27]. To confirm the
physiological relevance of these findings we blocked
GABAA receptors or strychnine-sensitive glycine recep-
tor in the vicinity of CVPN and examined the response
of systemic 8-OH-DPAT on the tonic and reflex brady-
cardia evoked. We found that intravenous 8-OH-DPAT
administration evoked bradycardia and potentiated BRS
in the presence of GABAA receptor blockade whereas 8-
OH-DPAT failed to evoke a response when strychnine
sensitive glycine receptors were antagonised. It is unli-
kely that the ability of 8-OH-DPAT to improve BRS in
the presence of picrotoxin is related to the HR lowering
effects of picrotoxin. An inverse relationship does exist
between resting HR and BRS, such that the lower the
HR the greater the BRS [52]; however, if the ability for
8-OH-DPAT to improve BRS in the presence of picro-
toxin was solely due to a HR lowering effect of picro-
toxin then BRS should have improved following
microinjection of picrotoxin. As this was not the case,
this indicates that 8-OH-DPAT improves BRS indepen-
dent of the resting level of HR. Furthermore, our find-
ings indicate that the bradycardiac and baroreflex
enhancing effects of 8-OH-DPAT are dependent upon
functional glycinergic neurotransmission in the vicinity
of CVPN.
The finding that 8-OH-DPAT acts via a glycinergic
mechanism was surprising as microinjection of strych-
nine did not affect HR or BRS. As 5-HT1A receptors are
purported to be tonically involved in the reflex activa-
tion of CVPN [22,24], we expected that if 8-OH-DPAT
were acting on glycinergic neurons directly innervating
CVPN then strychnine would mimic the effects of 8-
OH-DPAT. While we cannot reconcile this perplexing
finding, a previous in vitro study indicated that glyciner-
g i ci n p u t st oC V P Na r em o r es e n s i t i v et o8 - O H - D P A T
than GABAergic inputs providing some support for our
findings. The location of the 5-HT1A receptor with
respect to both CVPN and glycinergic input is
unknown. Our current hypothesis is that the 5-HT1A
receptor is located upstream of a glycinergic input to
CVPN.
Conclusions
Diseases including hypertension, depression and kidney
failure are associated with impaired function of vagal
inputs to the heart [53-55]. Understanding how neuro-
chemicals control cardiac vagal function is essential to
determining what can go wrong in disease. Until now
central neurochemical inputs to CVPN responsible for
the tonic and reflex control of HR have been poorly
investigated. Here we present a comprehensive investi-
gation of the role of ionotropic GABAergic, glycinergic
and glutamatergic inputs in the tonic and reflex control
of HR. We also provide a mechanism by which activa-
tion of 5-HT1A receptors can improve vagal outflow to
the heart. This is an important contribution as activa-
tion of 5-HT1A receptors does not improve baroreflex
function in rodent models of depression suggesting that
the interaction between 5-HT1A receptors and glyciner-
gic neurons may be involved in the aetiology of abnor-
mal vagal control of HR in depression [23]. This study
enhances our understanding of neural control of the
heart and will provide a reference point for future stu-
dies examining central mechanisms responsible for
impaired cardiac vagal control in disease.
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